Micardis is a prescription-only pill that contains the active ingredient telmisartan. Telmisartan belongs to the class of drugs known as angiotensin II receptor blockers (ARBs) and is used to treat conditions related to high blood pressure and certain heart-related disorders. In Hong Kong, Micardis is regulated by the Pharmacy and Poisons Board and is available in three strengths: 20 mg, 40 mg, and 80 mg tablets.
Telmisartan blocks the binding of angiotensin II to the AT-1 receptors found on blood vessels and the adrenal gland. By preventing this interaction, the drug:
The onset of blood-pressure reduction usually occurs within a few hours, with peak effect reached after about 24 hours. Telmisartan has a long half-life (≈24 hours), allowing once-daily dosing.
Micardis is FDA- and EMA-approved for the following indications, which also apply under Hong Kong regulatory guidance:
These uses target adult patients; the medication is not intended for children or adolescents without a specific clinician order.
Clinical studies have shown that telmisartan can slow the decline of kidney function in patients with type 2 diabetes and micro-albuminuria. This use is not approved by the Hong Kong Department of Health and should only be considered under close medical supervision.
Off-label use requires individualized risk assessment and ongoing monitoring by a qualified healthcare professional.
If any of the above conditions apply, discuss alternatives with a healthcare provider.
These effects are usually mild and transient; they often improve with continued therapy.
Black-box warnings for ARBs focus on fetal toxicity and the risk of angioedema.
Standard adult dosing:
Start with 40 mg once daily.
If needed, the dose may be increased to 80 mg once daily based on blood-pressure response.
For patients with renal impairment or the elderly, begin with 20 mg once daily and titrate cautiously.
Administration: Swallow the tablet whole with a glass of water. Do not crush or chew unless a specific preparation is advised by a pharmacist.
Missed dose: Take the missed tablet as soon as remembered on the same day; if it is almost time for the next dose, skip the missed one and continue the regular schedule. Do not double-dose.
Overdose: Symptoms may include severe hypotension, rapid heartbeat, and dizziness. Seek immediate medical attention; treatment is supportive (e.g., intravenous fluids, vasopressors). No specific antidote is available.
Discontinuation: Gradual tapering is not required for telmisartan, but stopping abruptly may cause rebound hypertension in some patients. Follow up with a clinician for a safe cessation plan.
Regular follow-up visits allow dose adjustments and early detection of adverse events.
This article provides educational information about Micardis and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Yes, Micardis can be combined with other antihypertensives such as thiazide diuretics or calcium-channel blockers to achieve better blood-pressure control. However, concurrent use with other ARBs or ACE inhibitors is generally avoided due to the increased risk of hyperkalemia and renal impairment.
In Hong Kong the 20 mg, 40 mg, and 80 mg tablets have distinct colors and imprint codes that help differentiate strengths. For example, 20 mg tablets may be white with a specific imprint, while 80 mg tablets are often pink with a different code. Always verify the imprint against the pharmacy label.
Micardis is not a controlled substance and is not screened for in standard workplace drug-testing panels. It will only be detected if a specific test for ARBs is ordered, which is uncommon.
Yes, but carry the medication in its original labeled container and bring a copy of the prescription. Some countries require documentation for prescription medicines; having a doctor’s note in English can facilitate customs clearance.
Transitioning between ARBs is generally safe, but a brief overlap is unnecessary. Your healthcare provider may advise a direct switch, monitoring blood pressure and renal function during the first few weeks.
Both drugs block the same receptor, but telmisartan has a longer half-life, allowing once-daily dosing without the need for multiple doses. Some studies suggest telmisartan may offer modest additional benefits in metabolic parameters, though clinical outcomes are comparable.
No special dietary restrictions are required. However, maintaining a consistent sodium intake supports optimal blood-pressure control, and excessive salty foods can counteract the drug’s effect.
Take the missed tablet as soon as you remember on the same day, unless it is close to the time of your next scheduled dose. In that case, skip the missed dose and resume your regular dosing schedule. Do not double the dose to catch up.
The tablets remain stable for the duration of the labeled expiration date when stored properly. Exposure to high humidity or heat can degrade the product faster, so keep the bottle tightly closed in a dry environment.
Generic telmisartan formulations are produced by multiple manufacturers after patent expiry, leading to market competition and lower prices. The active ingredient is identical, but inactive excipients may differ slightly; efficacy and safety remain comparable under regulatory approval.
